Abstract
C11H15NO3S, orthorhombic, Pna21 (no. 33), a = 9.5337(10) Å, b = 10.7168(11) Å, c = 11.5675(11) Å, V = 1181.9(2) Å3, Z = 4, Rgt(F) = 0.0252, wRref(F2) = 0.0689, T = 173 K.
The asymmetric unit of the title crystal structure is shown in the figure. Tables 1 and 2 contain details of the measurement method and a list of the atoms including atomic coordinates and displacement parameters.
Data collection and handling.
Crystal: | Colourless rod |
Size: | 0.35 × 0.22 × 0.13 mm |
Wavelength: | Mo Kα radiation (0.71073 Å) |
μ: | 2.7 cm−1 |
Diffractometer, scan mode: | Bruker APEX-II, φ and ω |
2θmax, completeness: | 51°, >99% |
N(hkl)measured, N(hkl)unique, Rint: | 6515, 2182, 0.030 |
Criterion for Iobs, N(hkl)gt: | Iobs > 2 σ(Iobs), 2165 |
N(param)refined: | 147 |
Programs: | Bruker programs [1, 2] , SHELX [3], ORTEP-3 [4] |
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).
Atom | x | y | z | Uiso*/Ueq |
---|---|---|---|---|
C1 | 0.9431(2) | 0.0504(2) | 1.01470(19) | 0.0143(5) |
C2 | 0.8834(2) | −0.0146(2) | 1.1060(2) | 0.0174(5) |
H2 | 0.799584 | 0.014566 | 1.141348 | 0.021* |
C3 | 0.9480(3) | −0.1230(2) | 1.1451(2) | 0.0204(5) |
H3 | 0.908463 | −0.168381 | 1.207648 | 0.024* |
C4 | 1.0706(2) | −0.1653(2) | 1.0926(2) | 0.0208(5) |
H4 | 1.114818 | −0.239137 | 1.119661 | 0.025* |
C5 | 1.1280(2) | −0.0996(2) | 1.0011(2) | 0.0188(5) |
H5 | 1.211468 | −0.128958 | 0.965504 | 0.023* |
C6 | 1.0650(2) | 0.0084(2) | 0.9609(2) | 0.0165(4) |
H6 | 1.104166 | 0.053032 | 0.897766 | 0.020* |
C7 | 0.9550(2) | 0.3748(2) | 0.86506(19) | 0.0132(4) |
C8 | 1.0808(2) | 0.5492(2) | 0.7767(2) | 0.0164(5) |
C9 | 0.9718(2) | 0.6497(2) | 0.7992(2) | 0.0221(5) |
H9A | 0.980867 | 0.715584 | 0.740876 | 0.033* |
H9B | 0.877792 | 0.613103 | 0.794808 | 0.033* |
H9C | 0.986575 | 0.685250 | 0.876257 | 0.033* |
C10 | 1.0704(3) | 0.4934(2) | 0.6563(2) | 0.0219(5) |
H10A | 1.079151 | 0.559802 | 0.598540 | 0.033* |
H10B | 1.145864 | 0.432406 | 0.645298 | 0.033* |
H10C | 0.979451 | 0.451844 | 0.647370 | 0.033* |
C11 | 1.2279(2) | 0.5987(2) | 0.7986(2) | 0.0225(5) |
H11A | 1.248103 | 0.666469 | 0.744200 | 0.034* |
H11B | 1.234258 | 0.630202 | 0.877920 | 0.034* |
H11C | 1.296101 | 0.531287 | 0.787675 | 0.034* |
N1 | 0.97629(18) | 0.27716(16) | 0.94124(16) | 0.0139(4) |
H1 | 1.055026 | 0.268412 | 0.980118 | 0.017* |
O1 | 1.06762(15) | 0.44860(15) | 0.86515(14) | 0.0156(4) |
O2 | 0.84904(14) | 0.38734(16) | 0.80861(15) | 0.0178(4) |
O3 | 0.74651(15) | 0.21720(15) | 1.04930(13) | 0.0161(4) |
S1 | 0.84269(5) | 0.17653(4) | 0.95484(5) | 0.01270(18) |
Source of material
The title compound was prepared from benzenesulfinamide according to the literature procedure [5]. In a round bottom flask, benzenesulfinamide 3 (0.40 g, 2.80 mmol) was dissolved in dry THF (12 mL) and cooled to −78 °C. After stirring the mixture for 10 min at −78 °C, n-butyl lithium (2.80 mL, 7.10 mmol) was added dropwise over 10 min. The mixture was stirred for 10 more minutes at −78 °C, followed by rapid addition of di-tert-butyl dicarbonate (0.742 g, 3.40 mmol), stirring was continued for 10 min at −78°C which gradually raised the temperature to RT and stirred overnight at room temperature. A saturated solution of NaHCO3 was then added and diluted with dichloromethane. The water phase was extracted with dichloromethane, dried over MgSO4, filtered, and concentrated under reduced pressure. Flash chromatography using dichloromethane as eluent yielded the title compound (0.306 g, 45%) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ ppm 10.49 (s, 1H), 7.68–7.66 (m, 2H), 7.59–7.56 (m, 3H), 1.44 (s, 9H). 13C NMR (125 MHz, DMSO-d6) δ ppm 153.40, 143.49, 131.26, 128.97, 124.93, 81.47, 27.75. The title compound (10 mg) was dissolved in acetonitrile in a vial by sonication for 3 min. The vial was covered with parafilm with a tiny outlet to enable evaporate ion. Crystals suitable for X-ray diffraction formed over the period of 5 days.
Experimental details
The data were scaled and absorption correction performed using SADABS [1]. The structure was solved by direct methods using SHELXS-97 [3]. All hydrogen atoms were placed in idealised positions and refined in riding models with Uiso assigned the values to be 1.2 or 1.5 times those of their parent atoms and the constraint distances of CH ranging from 0.95 Å to 1.00 Å.
Discussion
Bioisosterism is an advantageous approach in medicinal chemistry, which facilitates the greater selectivity for a determined receptor or enzymatic isoform subtype. It can result in less side effects, decreased toxicity, improved solubility-hydrophobicity and different/better metabolic stability [6, 7] . Sulphur isosters viz. sulfines, sulfoximines, sulfonimidamides, sulfonamides, are the compounds of much interest in pharamceutical chemistry [8]. Sulfonamides are found to be an integral part of more than hundred approved drugs or molecules in clinical trials. Sulfonimidamide is an isostere of sulphonamide, which is formed by replacing one of the O-atoms by nitrogen of sulfonamide. The title compound can be considered as a potential pecursor for the preparation of sulfonimidamids [9], [10], [11], [12]. However crystal structures of sulfinylcarbamate derivatives are rare.
Crystal structure of the title compound shows that the sulfinyl (S=O) group is perpendicular to the amide bond of the molecule as it is observed in the crystal structures of most of the sulfonylcarbamate derivatives. The major interactions among molecules in the crystal structure of the title compound are established by N—H⋯O=S hydrogen bonds [d(N⋯O) = 2.864 Å] formed by sulfinyl and amide groups. From the CSD analysis it was noticed that this type of interactions occured only in a few cases of sulfonyl derivatives, while in most of the cases the major interactions among molecules in the crystals were established through the amide groups. In addition to N—H⋯O hydrogen bonds, the C—H⋯O secondary interactions formed by the carbonyl (C=O) and aromatic H-atoms are also involved in connecting adjacent molecules forming hydrogen bonded 1D tape-like arrangment running along [100] and such tapes are connected through various very weak C—H⋯O and C—H⋯π interactions.
References
1 Bruker. SAINT, APEX2 and SADABS. Bruker AXS Inc., Madison, WI, USA (2004).Suche in Google Scholar
2 Bruker. XPREP (version 5.1/NT). Bruker AXS Inc., Madison, WI, USA (1997).Suche in Google Scholar
3 Sheldrick, G. M.: Crystal structure refinement with SHELXL. Acta Crystallogr. C71 (2015) 3–8.10.1107/S2053229614024218Suche in Google Scholar PubMed PubMed Central
4 Farrugia, L. J.: ORTEP-3 for Windows − a version of ORTEP-III with a Graphical User Interface. J. Appl. Crystallogr. 30 (1997) 565–565.10.1107/S0021889897003117Suche in Google Scholar
5 Funes, M.; Sehgelmeble, F.; Bjarnemark, F.; Svensson, M.; Åhman, J.; Arvidsson, P. I.: Synthesis and arylation of unprotected sulfonimidamides. Tetrahedron 68 (2012) 7456–7462.10.1016/j.tet.2012.06.072Suche in Google Scholar
6 Patani, G. A.; LaVoie, E. J.: Bioisosterism: a rational approach in drug design. Chem. Rev. 96 (1996) 3147–3176.10.1021/cr950066qSuche in Google Scholar PubMed
7 Lima, L. M.; Barreiro, E. J.: Bioisosterism: a useful strategy for molecular modification and drug design. Curr. Med. Chem. 12 (2005) 23–49.10.2174/0929867053363540Suche in Google Scholar PubMed
8 Lücking, U.: Sulfoximines: a neglected opportunity in medicinal chemistry. Angew. Chem. Int. Ed. 52 (2013) 9399–9408.10.1002/anie.201302209Suche in Google Scholar PubMed
9 Borhade, S. R.; Svensson, R.; Brandt, P.; Artursson, P.; Arvidsson, P. I.; Sandström, A.: Preclinical characterization of acyl sulfonimidamides: potential carboxylic acid bioisosteres with tunable properties. ChemMedChem 10 (2015) 455–460.10.1002/cmdc.201402497Suche in Google Scholar PubMed
10 Nandi, G. C.; Kota, S. R.; Naicker, T.; Govender, T.; Kruger, H. G.; Arvidsson, P. I.: Cu(OAc)2-catalysed oxidative dual C–H/N–H activation of terminal alkynes and N-deprotected sulfonimidamides: an easy access to N-alkynylated sulfonimidamides. Eur. J. Org. Chem. 2015 (2015) 2861–2867.10.1002/ejoc.201500239Suche in Google Scholar
11 Pemberton, N.; Graden, H.; Evertsson, E.; Bratt, E.; Lepistö, M.; Johannesson, P.; Svensson, P. H.: Synthesis and functionalization of cyclic sulfonimidamides: a novel chiral heterocyclic carboxylic acid bioisostere. ACS Med. Chem. Lett. 3 (2012) 574–578.10.1021/ml3000935Suche in Google Scholar PubMed PubMed Central
12 Sehgelmeble, F.; Janson, J.; Ray, C.; Rosqvist, S.; Gustavsson, S.; Nilsson, L. I.; Minidis, A.; Holenz, J.; Rotticci, D.; Lundkvist, J.; Arvidsson, P. I.: Sulfonimidamides as sulfonamides bioisosteres: rational evaluation through synthetic, in vitro, and in vivo studies with γ-secretase inhibitors. ChemMedChem 7 (2012) 396–399.10.1002/cmdc.201200014Suche in Google Scholar PubMed
©2017 Parameshwar Makam et al., published by De Gruyter.
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Artikel in diesem Heft
- Cover and Frontmatter
- Crystal structure of poly[diaqua-(μ2-4,4′-bipyridine-κ2N:N′)manganese(II)] bis(4-chlorobenzenesulfonate) – 4,4′-bipyridine – water (1/1/2) C42H40Cl2MnN6O10S2
- The crystal structure of 1,2-bis[2-methyl-5-(3-cyanophenyl)-3-thienyl]-3,3,4,4,5,5-hexafluoro-cyclopent-1-ene, C29H16F6N2S2
- Crystal structure of the first characterized polymeric copper and sodium complex diaqua-(tris-acetato-κO,O′)(μ2-acetato-κO′′)dinatrium copper(II) monohydrate, C8H18CuNa2O11
- The crystal structure of the Schiff base (E)-2,6-diisopropyl-N-(pyridin-3-yl-methylene)aniline, C18H22N2
- Crystal structure of methyl 2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylate, C20H22N2O5
- Crystal structure of bis(1,3-bis(diphenylphosphino)propane-κ2P,P′)silver(I) trifluorosulfonate–methanol (1:0.5), [Ag(C27H26P2)]SO3CF3⋅0.5CH3OH
- Crystal structure of μ-1,4-bis(diphenylphosphine)butane-2,9-dimethyl-1,10-phenanthroline-κ2N:N′-bis(cyano-κC)dicopper(I)]-water, C58H56Cu2N6O2P2
- Crystal structure of N2,N6-bis(1-hydrazinyl-2-methyl-1-oxopropan-2-yl) pyridine-2,6-dicarboxamide, C15H23N7O4
- Crystal structure of 1,3-dimethyl-2-phenyl-1H-perimidin-3-ium iodide, C19H17IN2
- Crystal structure of diaqua-(2,2′-(butane-1,4-diyl)-bis(5-carboxy-1H-imidazole-4-carboxylato)-κ4O,O′,N,N′)cadmium(II) monohydrate, C14H18O11N4Cd
- Crystal structure of ethyl (E)-3-(cyclopropylamino)-2-(2,4-dichloro-5-fluorobenzoyl) acrylate, C15H14Cl2FNO3
- Crystal structure of bis-(1-(4-chlorophenyl)-3-phenyl-4-thenoyl-1H-pyrazol-5-ol-κ2O,O′)-(N,N-dimethylformamide)zinc(II), C43H31Cl2N5O5S2Zn
- Crystal structure of tetrakis(μ3-2-(N-(2-hydroxyethyl)amino)ethoxo)-tetrachloro-tetra-cobalt(II) methanol solvate, C17H44Cl4Co4N4O9
- Crystal structure of 3-amino-1-(4-bromophenyl)-9-methoxy-1H-benzo[f]chromene-2-carbonitrile, C21H15BrN2O2
- Crystal structure of 2-amino-4-(4-isopropyl-phenyl)-3-cyano-5-oxo-4H,5H-pyrano[3,2-c]chromene, C22H18N2O3
- Crystal structure of 3-amino-8-methoxy-1-(4-methoxy phenyl)-1H-benzo[f]chromene-2-carbonitrile, C22H18N2O3
- Crystal structure of monoaqua-[6,6′-((1E,1′E)-(1,2-phenylene bis(azanylylidene))bis(methanylylidene))bis(4-bromo-2-nitrophenolato-κ4N,N′,O,O′)]zinc(II), C20H12Br2N4O7Zn
- Crystal structure of 11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one – acetonitril (1/2), C33H41N3O2
- Crystal structure of tert-butyl (phenylsulfinyl)carbamate, C11H15NO3S
- Crystal structure of catena-poly{diaqua-bis(3-(1H-1,2,4-triazol-1-yl)benzoato-κ2O:N)copper(II)} monohydrate, C18H18CuN6O7
- Crystal structure of tetraaqua-bis(3-(4H-1,2,4-triazol-4-yl)benzoato-κN)cobalt(II), C18H20CoN6O8
- The crystal structure of 4-bromo-N-cyclopropyl-2,5-difluorobenzenesulfonamide, C9H8BrF2NO2S
- Crystal structure of ([3,3′-bipyridine]-6,6′-dicarboxylato-κ2O:O′)-bis(1,2-bis(4-pyridyl)ethane-κ2N:N′)disilver(I) dihydrate, C37H35Ag2N5O6
- The crystal structure of (4-(1H-1,2,4-triazol-1-yl)benzoato-κN)-[4-(1H-1,2,4-triazol-1-yl)benzoic acid-κN]silver(I), C18H13AgN6O4
- Crystal structure of 3-(4-methoxyphenyl)-1-(4-methylphenyl)prop-2-en-1-one, C17H16O2
- Crystal structure of bis(2-((E)-((4-((E)-1-(ethoxyimino)ethyl)phenyl)imino)methyl)-5-methoxyphenolato-κ2O,N)copper(II), C36H38CuN4O6
- Crystal structure of poly[1,2-bis(1,2,4-triazol-4-yl)ethane-κ2N:N′]silver(I) bromate monohydrate]silver(I), C6H10AgBrN6O4
- The crystal structure of 2,3,5-triphenyl-2,3-dihydro-1H-tetrazol-1-ium 2,3-dioxoindoline-5-sulfonate, C27H19N5O5S
- Crystal structure of 3-(2-amino-1,3-selenazol-4-yl)-2H-chromen-2-one – dimethylformamide (1/1), C15H15N3O3Se
- Crystal structure of diethyl 3,3′-(diazene-1,2-diyl)(E)-dibenzoate, C18H18N2O4
- Crystal structure of cis-bis((1H-benzimidazol-2-yl)methanol-κN,O)-bis(isothiocyanato-κN)nickel(II), C18H16N6NiO2S2
- Crystal structure of bis(2-(2′-hydroxy-5′-methoxyphenyl)-1H-benzimidazole)boron – tetrahydrofuran (1/1), C36H37N4O6B
- Crystal structure of poly[aqua-bis(nitrato-κ2O,O′)-(μ3-1,3-benzimidazol-3-ium-1,3-diacetato-κ4O,O′:O′′:O′′′)dysprosium(III)], C11H11DyN4O11
- Crystal structure of n-butyl-tris(dicyclo-hexylamido)hafnium(IV), C40H75HfN3
- Crystal structure of (E)-1-[1-(3-chloro-4-fluoro-phenyl)ethylidene]-2-(2,4-dinitrophenyl)hydrazine, C28H20Cl2F2N8O8
- The crystal structure of ethyl 4-((2-hydroxybenzyl)amino)benzoate, a Schiff base, C16H17NO3
- Crystal structure of 3-(2-(4-isobutylphenyl)propanoyl)-1-methylimidazolidine-2,4-dione, C17H22N2O3
- Crystal structure of poly[(μ3-2-(pyrazin-2-ylthio)acetato-κ3N:O:S)silver(I)], C6H5AgN2O2S
- Crystal structure of (E)-1-(3-((E)-((2-hydroxynaphthalen-1-yl)methylene)amino)phenyl)ethanone O-benzyl oxime, C26H22N2O2
- Crystal structure of (E)-2,3-dihydroxybenzaldehyde O-(2-((((E)-1-(2,5-dihydroxyphenyl)ethylidene)amino)oxy)ethyl) oxime monohydrate, C17H20N2O7
- Crystal structure of 4-(chloromethyl)-3-nitrobenzoic acid, C8H6ClNO4
- Crystal stucture of 4-((10H-phenothiazin-10-yl)methyl)-2,6-di-tert-butylphenol, C27H31NOS
- The crystal structure of ethyl 1-(4-nitrophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, C13H10F3N3O4
- Crystal structure of catena-poly[di-(μ3-oxido-κ3O:O:O)-tetraoxido-(μ2-5′-(pyrazin-2-yl)-1H,2′H-3,3′-bi(1,2,4-triazole)-κ2N:N′)dimolybdenum(VI)], C8H6Mo2N8O6
- Crystal structure of (3,6-dioxocyclohexa-1,4-diene-1,4-bis(olato)-κ4O,O′:O′′,O′′′)-bis(tris(2-pyridylmethyl)amine-κ4N,N′,N′′,N′′′))-dizinc(II) bis(hexafluorophosphate(V)), C42H38F12N8O4P2Zn2
- Crystal structure of catena-poly[hexakis(μ2-2-acetylphenolato-κ3O:O,O′)trimanganese(II)], C48H42Mn3O12
- The crystal structure of 2,2-difluoro-4-(trifluoromethyl)-2,5-dihydro-[1,3,2]dioxaborinino[5,4-c]chromen-3-ium-2-uide, C11H6BF5O3
- Crystal structure of methyl (E)-2-(4-(diethylamino)-2-hydroxybenzylidene)hydrazine-1-carboxylate, C13H19N3O3
- The crystal structure of tert-butyl 2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate, C10H15N3O2
- Crystal structure of 1,1-bis(η5-adamantylcyclopentadienyl)-3-phenyl-2-trimethylsilyl-2,3-dihydroisotitanazole, C42H55NSiTi
- Crystal structure of 2-(4-(2-(4-benzylpiperazin-1-yl)ethyl)benzyl)isoindoline-1,3-dione, C28H29N3O2
- Important impurity of Flupirtine – a single crystal study on ethyl (6-amino-5-((ethoxycarbonyl)amino)pyridin-2-yl)(4-fluorobenzyl)carbamate, C18H21FN4O4
- Crystal structure of ethyl 3-(4-methoxyphenyl)-1-(2-(4-methoxyphenyl)-2-oxoethyl)-1H-pyrazole-5-carboxylate, C22H22N2O5
- Crystal structure of 2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium 5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-olate methanol solvate, C37H35N1O10
- The crystal structure of the inner salt of 2-[(aminoiminomethyl)amino]ethylcarbamic acid [systematic name: (2-((diaminomethylene)ammonio)ethyl)carbamate], C4H10N4O2
- Crystal structure of (8-hydroxy-5-nitroquinolinium) perchlorate – 8-hydroxy-5-nitroquinoline (1/1), C18H13ClN4O10
- The crystal structure of (5-methyl-1,2,4-oxadiazol-3-yl)ferrocene, C13H12FeN2O
- Crystal structure of methyl 1-(2-(fluorosulfonyl)ethyl)-2-oxocyclopentanecarboxylate, C9H13FO5S
- Crystal structure of the triclinic modification of 1-methyl-4-nitroimidzole, C4H5N3O2
- Corrigendum
- Crystal structure of 4-bromo-2-(1H-pyrazol-3-yl)phenol, C9H7BrN2O
Artikel in diesem Heft
- Cover and Frontmatter
- Crystal structure of poly[diaqua-(μ2-4,4′-bipyridine-κ2N:N′)manganese(II)] bis(4-chlorobenzenesulfonate) – 4,4′-bipyridine – water (1/1/2) C42H40Cl2MnN6O10S2
- The crystal structure of 1,2-bis[2-methyl-5-(3-cyanophenyl)-3-thienyl]-3,3,4,4,5,5-hexafluoro-cyclopent-1-ene, C29H16F6N2S2
- Crystal structure of the first characterized polymeric copper and sodium complex diaqua-(tris-acetato-κO,O′)(μ2-acetato-κO′′)dinatrium copper(II) monohydrate, C8H18CuNa2O11
- The crystal structure of the Schiff base (E)-2,6-diisopropyl-N-(pyridin-3-yl-methylene)aniline, C18H22N2
- Crystal structure of methyl 2,7,7-trimethyl-4-(4-nitrophenyl)-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylate, C20H22N2O5
- Crystal structure of bis(1,3-bis(diphenylphosphino)propane-κ2P,P′)silver(I) trifluorosulfonate–methanol (1:0.5), [Ag(C27H26P2)]SO3CF3⋅0.5CH3OH
- Crystal structure of μ-1,4-bis(diphenylphosphine)butane-2,9-dimethyl-1,10-phenanthroline-κ2N:N′-bis(cyano-κC)dicopper(I)]-water, C58H56Cu2N6O2P2
- Crystal structure of N2,N6-bis(1-hydrazinyl-2-methyl-1-oxopropan-2-yl) pyridine-2,6-dicarboxamide, C15H23N7O4
- Crystal structure of 1,3-dimethyl-2-phenyl-1H-perimidin-3-ium iodide, C19H17IN2
- Crystal structure of diaqua-(2,2′-(butane-1,4-diyl)-bis(5-carboxy-1H-imidazole-4-carboxylato)-κ4O,O′,N,N′)cadmium(II) monohydrate, C14H18O11N4Cd
- Crystal structure of ethyl (E)-3-(cyclopropylamino)-2-(2,4-dichloro-5-fluorobenzoyl) acrylate, C15H14Cl2FNO3
- Crystal structure of bis-(1-(4-chlorophenyl)-3-phenyl-4-thenoyl-1H-pyrazol-5-ol-κ2O,O′)-(N,N-dimethylformamide)zinc(II), C43H31Cl2N5O5S2Zn
- Crystal structure of tetrakis(μ3-2-(N-(2-hydroxyethyl)amino)ethoxo)-tetrachloro-tetra-cobalt(II) methanol solvate, C17H44Cl4Co4N4O9
- Crystal structure of 3-amino-1-(4-bromophenyl)-9-methoxy-1H-benzo[f]chromene-2-carbonitrile, C21H15BrN2O2
- Crystal structure of 2-amino-4-(4-isopropyl-phenyl)-3-cyano-5-oxo-4H,5H-pyrano[3,2-c]chromene, C22H18N2O3
- Crystal structure of 3-amino-8-methoxy-1-(4-methoxy phenyl)-1H-benzo[f]chromene-2-carbonitrile, C22H18N2O3
- Crystal structure of monoaqua-[6,6′-((1E,1′E)-(1,2-phenylene bis(azanylylidene))bis(methanylylidene))bis(4-bromo-2-nitrophenolato-κ4N,N′,O,O′)]zinc(II), C20H12Br2N4O7Zn
- Crystal structure of 11-(4-(dimethylamino)phenyl)-17-hydroxy-13-methyl-17-(prop-1-yn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one – acetonitril (1/2), C33H41N3O2
- Crystal structure of tert-butyl (phenylsulfinyl)carbamate, C11H15NO3S
- Crystal structure of catena-poly{diaqua-bis(3-(1H-1,2,4-triazol-1-yl)benzoato-κ2O:N)copper(II)} monohydrate, C18H18CuN6O7
- Crystal structure of tetraaqua-bis(3-(4H-1,2,4-triazol-4-yl)benzoato-κN)cobalt(II), C18H20CoN6O8
- The crystal structure of 4-bromo-N-cyclopropyl-2,5-difluorobenzenesulfonamide, C9H8BrF2NO2S
- Crystal structure of ([3,3′-bipyridine]-6,6′-dicarboxylato-κ2O:O′)-bis(1,2-bis(4-pyridyl)ethane-κ2N:N′)disilver(I) dihydrate, C37H35Ag2N5O6
- The crystal structure of (4-(1H-1,2,4-triazol-1-yl)benzoato-κN)-[4-(1H-1,2,4-triazol-1-yl)benzoic acid-κN]silver(I), C18H13AgN6O4
- Crystal structure of 3-(4-methoxyphenyl)-1-(4-methylphenyl)prop-2-en-1-one, C17H16O2
- Crystal structure of bis(2-((E)-((4-((E)-1-(ethoxyimino)ethyl)phenyl)imino)methyl)-5-methoxyphenolato-κ2O,N)copper(II), C36H38CuN4O6
- Crystal structure of poly[1,2-bis(1,2,4-triazol-4-yl)ethane-κ2N:N′]silver(I) bromate monohydrate]silver(I), C6H10AgBrN6O4
- The crystal structure of 2,3,5-triphenyl-2,3-dihydro-1H-tetrazol-1-ium 2,3-dioxoindoline-5-sulfonate, C27H19N5O5S
- Crystal structure of 3-(2-amino-1,3-selenazol-4-yl)-2H-chromen-2-one – dimethylformamide (1/1), C15H15N3O3Se
- Crystal structure of diethyl 3,3′-(diazene-1,2-diyl)(E)-dibenzoate, C18H18N2O4
- Crystal structure of cis-bis((1H-benzimidazol-2-yl)methanol-κN,O)-bis(isothiocyanato-κN)nickel(II), C18H16N6NiO2S2
- Crystal structure of bis(2-(2′-hydroxy-5′-methoxyphenyl)-1H-benzimidazole)boron – tetrahydrofuran (1/1), C36H37N4O6B
- Crystal structure of poly[aqua-bis(nitrato-κ2O,O′)-(μ3-1,3-benzimidazol-3-ium-1,3-diacetato-κ4O,O′:O′′:O′′′)dysprosium(III)], C11H11DyN4O11
- Crystal structure of n-butyl-tris(dicyclo-hexylamido)hafnium(IV), C40H75HfN3
- Crystal structure of (E)-1-[1-(3-chloro-4-fluoro-phenyl)ethylidene]-2-(2,4-dinitrophenyl)hydrazine, C28H20Cl2F2N8O8
- The crystal structure of ethyl 4-((2-hydroxybenzyl)amino)benzoate, a Schiff base, C16H17NO3
- Crystal structure of 3-(2-(4-isobutylphenyl)propanoyl)-1-methylimidazolidine-2,4-dione, C17H22N2O3
- Crystal structure of poly[(μ3-2-(pyrazin-2-ylthio)acetato-κ3N:O:S)silver(I)], C6H5AgN2O2S
- Crystal structure of (E)-1-(3-((E)-((2-hydroxynaphthalen-1-yl)methylene)amino)phenyl)ethanone O-benzyl oxime, C26H22N2O2
- Crystal structure of (E)-2,3-dihydroxybenzaldehyde O-(2-((((E)-1-(2,5-dihydroxyphenyl)ethylidene)amino)oxy)ethyl) oxime monohydrate, C17H20N2O7
- Crystal structure of 4-(chloromethyl)-3-nitrobenzoic acid, C8H6ClNO4
- Crystal stucture of 4-((10H-phenothiazin-10-yl)methyl)-2,6-di-tert-butylphenol, C27H31NOS
- The crystal structure of ethyl 1-(4-nitrophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate, C13H10F3N3O4
- Crystal structure of catena-poly[di-(μ3-oxido-κ3O:O:O)-tetraoxido-(μ2-5′-(pyrazin-2-yl)-1H,2′H-3,3′-bi(1,2,4-triazole)-κ2N:N′)dimolybdenum(VI)], C8H6Mo2N8O6
- Crystal structure of (3,6-dioxocyclohexa-1,4-diene-1,4-bis(olato)-κ4O,O′:O′′,O′′′)-bis(tris(2-pyridylmethyl)amine-κ4N,N′,N′′,N′′′))-dizinc(II) bis(hexafluorophosphate(V)), C42H38F12N8O4P2Zn2
- Crystal structure of catena-poly[hexakis(μ2-2-acetylphenolato-κ3O:O,O′)trimanganese(II)], C48H42Mn3O12
- The crystal structure of 2,2-difluoro-4-(trifluoromethyl)-2,5-dihydro-[1,3,2]dioxaborinino[5,4-c]chromen-3-ium-2-uide, C11H6BF5O3
- Crystal structure of methyl (E)-2-(4-(diethylamino)-2-hydroxybenzylidene)hydrazine-1-carboxylate, C13H19N3O3
- The crystal structure of tert-butyl 2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate, C10H15N3O2
- Crystal structure of 1,1-bis(η5-adamantylcyclopentadienyl)-3-phenyl-2-trimethylsilyl-2,3-dihydroisotitanazole, C42H55NSiTi
- Crystal structure of 2-(4-(2-(4-benzylpiperazin-1-yl)ethyl)benzyl)isoindoline-1,3-dione, C28H29N3O2
- Important impurity of Flupirtine – a single crystal study on ethyl (6-amino-5-((ethoxycarbonyl)amino)pyridin-2-yl)(4-fluorobenzyl)carbamate, C18H21FN4O4
- Crystal structure of ethyl 3-(4-methoxyphenyl)-1-(2-(4-methoxyphenyl)-2-oxoethyl)-1H-pyrazole-5-carboxylate, C22H22N2O5
- Crystal structure of 2,3,9,10-tetramethoxy-5,6-dihydroisoquinolino[2,1-b]isoquinolin-7-ium 5-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-7-olate methanol solvate, C37H35N1O10
- The crystal structure of the inner salt of 2-[(aminoiminomethyl)amino]ethylcarbamic acid [systematic name: (2-((diaminomethylene)ammonio)ethyl)carbamate], C4H10N4O2
- Crystal structure of (8-hydroxy-5-nitroquinolinium) perchlorate – 8-hydroxy-5-nitroquinoline (1/1), C18H13ClN4O10
- The crystal structure of (5-methyl-1,2,4-oxadiazol-3-yl)ferrocene, C13H12FeN2O
- Crystal structure of methyl 1-(2-(fluorosulfonyl)ethyl)-2-oxocyclopentanecarboxylate, C9H13FO5S
- Crystal structure of the triclinic modification of 1-methyl-4-nitroimidzole, C4H5N3O2
- Corrigendum
- Crystal structure of 4-bromo-2-(1H-pyrazol-3-yl)phenol, C9H7BrN2O